Company:  INCYTE CORP (INCY)
Form Type:  10-Q
Filing Date:  8/3/2012 
CIK:  0000879169 
Address:  ROUTE 141 & HENRY CLAY ROAD
BUILDING E336
 
City, State, Zip:  WILMINGTON, Delaware 19880 
Telephone:  (302) 498-6700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$47.30  
Change: 
0.34 (0.72%)  
Trade Time: 
Apr 24  
Market Cap: 
$7.83B
Description of Business
Incyte is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. We have a broad pipeline with programs focused primarily in the areas of oncology and inflammation. We focus our efforts on clinical programs that we believe have the greatest likelihood of creating near-and long-term value and on compounds that we believe a company of our size can effectively develop and commercialize on its own, or that we can further develop and commercialize through strategic relationships. Our highest priority programs involve our janus kinase (JAK) inhibitors, which include oral INCB18424 for hematologic and oncology indications and oral INCB28050 for chronic inflammatory and autoimmune diseases.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I: FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II: OTHER INFORMATION
      Item 1A. Risk Factors
      Item 6. Exhibits
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
  EXHIBIT 32.2
BROKERAGE PARTNERS